ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers

Katia A. Mesquita(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Adel Alblihy(University of Nottingham), Paul M. Moseley(Nottingham University Hospitals NHS Trust), Tarek M.A. Abdel Fatah(Nottingham University Hospitals NHS Trust), Stephen Chan(Heidelberg University), Michaela Griffin(University of Nottingham), Michael S. Toss(Nottingham City Hospital), Muslim Alabdullah(Islamic Azad University, Science and Research Branch), Emad A. Rakha(Nottingham University Hospitals NHS Trust)
Gynecologic Oncology
February 21, 2019
10.1016/j.ygyno.2019.02.014
Cited by 45

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
|Journal of Clinical Oncology|1999|639
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374